William Ackman’s decision to finally throw in the towel on his Valeant Pharmaceuticals International investment after the embattled drug company’s stock helped to destroy his hedge funds’ performance is a painful reminder of the huge damage health care–related stocks have inflicted on many hedge funds, especially those that specialize in or have been heavily weighted toward the sector.
